RBC Capital Maintains Gilead at Sector Perform, Raises Target to $131

RBC Capital maintained its Sector Perform rating on Gilead Sciences and raised its price target to $131 from $126. The target implies 20.9% downside from the Oct. 29 close of $165.61.